Biosimulation Market Size, Top Share & Trends Report

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biosimulation Market Size Analysis

Global Biosimulation Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Software
    1. By Value
  3. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Drug Discovery & Development
    1. By Value
  3. Disease Modeling
    1. By Value
  4. Other (Precision Medicine, Toxicology, etc.)
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Neurological Disorders
    1. By Value
  6. Others
    1. By Value
4. By Deployment Model
  1. Introduction
    1. Deployment Model By Value
  2. Cloud-based
    1. By Value
  3. On-premise
    1. By Value
  4. Hybrid Model
    1. By Value
5. By Pricing Model
  1. Introduction
    1. Pricing Model By Value
  2. License-based Model
    1. By Value
  3. Subscription-based Model
    1. By Value
  4. Service-based Model
    1. By Value
  5. Pay Per Use Model
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Life Sciences Companies
    1. By Value
  3. Academic Research Institutions
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Software
    1. By Value
  3. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Drug Discovery & Development
    1. By Value
  3. Disease Modeling
    1. By Value
  4. Other (Precision Medicine, Toxicology, etc.)
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Neurological Disorders
    1. By Value
  6. Others
    1. By Value
4. By Deployment Model
  1. Introduction
    1. Deployment Model By Value
  2. Cloud-based
    1. By Value
  3. On-premise
    1. By Value
  4. Hybrid Model
    1. By Value
5. By Pricing Model
  1. Introduction
    1. Pricing Model By Value
  2. License-based Model
    1. By Value
  3. Subscription-based Model
    1. By Value
  4. Service-based Model
    1. By Value
  5. Pay Per Use Model
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Life Sciences Companies
    1. By Value
  3. Academic Research Institutions
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Software
    1. By Value
  3. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Drug Discovery & Development
    1. By Value
  3. Disease Modeling
    1. By Value
  4. Other (Precision Medicine, Toxicology, etc.)
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Neurological Disorders
    1. By Value
  6. Others
    1. By Value
4. By Deployment Model
  1. Introduction
    1. Deployment Model By Value
  2. Cloud-based
    1. By Value
  3. On-premise
    1. By Value
  4. Hybrid Model
    1. By Value
5. By Pricing Model
  1. Introduction
    1. Pricing Model By Value
  2. License-based Model
    1. By Value
  3. Subscription-based Model
    1. By Value
  4. Service-based Model
    1. By Value
  5. Pay Per Use Model
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Life Sciences Companies
    1. By Value
  3. Academic Research Institutions
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Software
    1. By Value
  3. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Drug Discovery & Development
    1. By Value
  3. Disease Modeling
    1. By Value
  4. Other (Precision Medicine, Toxicology, etc.)
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Neurological Disorders
    1. By Value
  6. Others
    1. By Value
4. By Deployment Model
  1. Introduction
    1. Deployment Model By Value
  2. Cloud-based
    1. By Value
  3. On-premise
    1. By Value
  4. Hybrid Model
    1. By Value
5. By Pricing Model
  1. Introduction
    1. Pricing Model By Value
  2. License-based Model
    1. By Value
  3. Subscription-based Model
    1. By Value
  4. Service-based Model
    1. By Value
  5. Pay Per Use Model
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Life Sciences Companies
    1. By Value
  3. Academic Research Institutions
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Software
  1. By Value
3. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Drug Discovery & Development
  1. By Value
3. Disease Modeling
  1. By Value
4. Other (Precision Medicine, Toxicology, etc.)
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Cardiovascular Disease
  1. By Value
4. Infectious Disease
  1. By Value
5. Neurological Disorders
  1. By Value
6. Others
  1. By Value
By Deployment Model
1. Introduction
  1. Deployment Model By Value
2. Cloud-based
  1. By Value
3. On-premise
  1. By Value
4. Hybrid Model
  1. By Value
By Pricing Model
1. Introduction
  1. Pricing Model By Value
2. License-based Model
  1. By Value
3. Subscription-based Model
  1. By Value
4. Service-based Model
  1. By Value
5. Pay Per Use Model
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Life Sciences Companies
  1. By Value
3. Academic Research Institutions
  1. By Value
4. Others
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Software
    1. By Value
  3. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Drug Discovery & Development
    1. By Value
  3. Disease Modeling
    1. By Value
  4. Other (Precision Medicine, Toxicology, etc.)
    1. By Value
3. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Cardiovascular Disease
    1. By Value
  4. Infectious Disease
    1. By Value
  5. Neurological Disorders
    1. By Value
  6. Others
    1. By Value
4. By Deployment Model
  1. Introduction
    1. Deployment Model By Value
  2. Cloud-based
    1. By Value
  3. On-premise
    1. By Value
  4. Hybrid Model
    1. By Value
5. By Pricing Model
  1. Introduction
    1. Pricing Model By Value
  2. License-based Model
    1. By Value
  3. Subscription-based Model
    1. By Value
  4. Service-based Model
    1. By Value
  5. Pay Per Use Model
    1. By Value
6. By End-User
  1. Introduction
    1. End-User By Value
  2. Life Sciences Companies
    1. By Value
  3. Academic Research Institutions
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biosimulation Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Certara, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Simulations Plus, Inc.
Dassault Systèmes
BIOVIA (Dassault Systèmes)
Schrodinger, Inc.
Pharmalex
Roche
GSK (GlaxoSmithKline)
AstraZeneca
Biorelate
Cyprotex
Accenture Life Sciences
Syneos Health
MaxCyte
InSilico Medicine

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment